Ponvory 2, 3, 4, 5, 6, 7, 8, 9, 10 And 20 Mg 2, 3, 4, 5, 6, 7, 8, 9, 10 and 20 mg Tablet
PDF Leaflet Revision Date: 19 September 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of adult patients with relapsing forms of multiple sclerosis.
Dosage (summary)
Initiate with 2 mg daily, titrate to 20 mg once daily.
Onset of Action / Duration
Onset: 1 hour, Duration: 24 hours
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; not recommended during breastfeeding.
Key Drug Interactions
- Anti-neoplastic therapies
- Immunosuppressive therapies
- QT prolonging medicines
Contraindications
- Hypersensitivity
- Severe hepatic impairment
- Recent myocardial infarction
- Pregnancy
Common side effects
- Lymphopenia
- Bradycardia
- Hypertension
- Macular oedema
Counselling Points
- Monitor for signs of infection.
- Use effective contraception during treatment.
- Regular eye exams recommended.
Serious warnings
- Risk of infections
- Brady-dysrhythmia
- Progressive multifocal leukoencephalopathy
Important Disclaimer
The Ponvory 2, 3, 4, 5, 6, 7, 8, 9, 10 And 20 Mg 2, 3, 4, 5, 6, 7, 8, 9, 10 and 20 mg Tablet professional information leaflet below is the property of Janssen Pharmaceutica and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
